This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ranke, C. Articles by Alexander, K. Search for Related Content PubMed PubMed Citation Articles by Ranke, C. Articles by Alexander, K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID Medline Plus Health Information Carotid Artery Disease

Circulation, Vol 87, 1873-1879, Copyright © 1993 by American Heart Association

ARTICLES

Dose-dependent effect of aspirin on carotid atherosclerosis

C Ranke, H Hecker, A Creutzig and K Alexander
Division of Angiology, Hannover Medical School, Germany.

BACKGROUND. Antiplatelet treatment with aspirin is well established as secondary prophylaxis after a transient ischemic attack or minor ischemic stroke, but the effect of aspirin treatment on the course of carotid atherosclerosis is unknown. We investigated the effect of aspirin on the initial stages of carotid atherosclerosis. METHODS AND RESULTS. Patients were recruited from a prospective, randomized, double- blind clinical trial to compare two doses of aspirin (900 mg versus 50 mg daily) with regard to restenoses after lower limb angioplasty. Of the 383 patients admitted to the angioplasty trial, 27 patients with 104 small carotid atheroma (< 50% lumen narrowing) were examined at entry and after 1 year of aspirin treatment with the use of a high- resolution ultrasound duplex system. Disease progression and regression were defined by a change of maximal plaque area (as measured by longitudinal ultrasound sections) of more than 2 SDs of the method. The change in plaque area was significantly different for the treatment groups: Average plaque size remained unchanged after treatment with 900 mg aspirin daily but increased markedly after treatment with 50 mg aspirin daily (p = 0.011). There were significantly more lesions in the 50-mg group showing progression than in the 900-mg group (23 plaques [47%] versus 13 plaques [24%], p = 0.025). Ultrasonic disappearance of a lesion was observed only in the 900-mg group in nine cases (seven soft plaques and two ulcerative plaques, p = 0.018). The six patients on 50 mg aspirin who continued smoking during the study showed significantly more progression compared with the seven nonsmokers in the 50-mg group (17 plaques [59%] versus six plaques [30%], p = 0.038). CONCLUSIONS. The results of our study indicate that aspirin treatment slows carotid plaque growth in a dose-dependent fashion, with a dose of 900 mg daily more efficient than 50 mg daily.

This article has been cited by other articles:

				W. S. Aronow Use of Antiplatelet Drugs in Secondary Prevention in Older Persons With Atherothrombotic Disease J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2007; 62(5): 518 - 524. [Abstract] [Full Text] [PDF]

				J. R. Crouse III Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art J. Lipid Res., August 1, 2006; 47(8): 1677 - 1699. [Abstract] [Full Text] [PDF]

				S. Fateh-Moghadam, Z. Li, S. Ersel, T. Reuter, P. Htun, U. Plockinger, W. Bocksch, R. Dietz, and M. Gawaz Platelet Degranulation Is Associated With Progression of Intima-Media Thickness of the Common Carotid Artery in Patients With Diabetes Mellitus Type 2 Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1299 - 1303. [Abstract] [Full Text] [PDF]

				N. Grosser and H. Schroder Aspirin Protects Endothelial Cells From Oxidant Damage Via the Nitric Oxide-cGMP Pathway Arterioscler. Thromb. Vasc. Biol., August 1, 2003; 23(8): 1345 - 1351. [Abstract] [Full Text] [PDF]

				T. Cyrus, S. Sung, L. Zhao, C. D. Funk, S. Tang, and D. Pratico Effect of Low-Dose Aspirin on Vascular Inflammation, Plaque Stability, and Atherogenesis in Low-Density Lipoprotein Receptor-Deficient Mice Circulation, September 3, 2002; 106(10): 1282 - 1287. [Abstract] [Full Text] [PDF]

				P. Wiesli, W. Czerwenka, A. Meniconi, F. E. Maly, U. Hoffmann, W. Vetter, and G. Schulthess Roxithromycin Treatment Prevents Progression of Peripheral Arterial Occlusive Disease in Chlamydia pneumoniae Seropositive Men: A Randomized, Double-Blind, Placebo-Controlled Trial Circulation, June 4, 2002; 105(22): 2646 - 2652. [Abstract] [Full Text] [PDF]

				C. Knottenbelt, P. J. Brennan, T. W. Meade, and for the Medical Research Council's General Practic Antithrombotic Treatment and the Incidence of Angina Pectoris Arch Intern Med, April 22, 2002; 162(8): 881 - 886. [Abstract] [Full Text] [PDF]

				R. Voisard, R. Fischer, M. O{beta}wald, S. Voglic, R. Baur, M. Susa, W. Koenig, and V. Hombach Aspirin (5 mmol/L) Inhibits Leukocyte Attack and Triggered Reactive Cell Proliferation in a 3D Human Coronary In Vitro Model Circulation, March 27, 2001; 103(12): 1688 - 1694. [Abstract] [Full Text] [PDF]

				D. Praticò, C. Tillmann, Z.-B. Zhang, H. Li, and G. A. FitzGerald Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice PNAS, March 1, 2001; (2001) 61607398. [Abstract] [Full Text]

				J. He, P. K. Whelton, B. Vu, and M. J. Klag Aspirin and Risk of Hemorrhagic Stroke: A Meta-analysis of Randomized Controlled Trials JAMA, December 9, 1998; 280(22): 1930 - 1935. [Abstract] [Full Text] [PDF]

				F. J. Vagnini, S. Hill, J. Puvogel, and J. Puvogel The Use of Multisite High Resolution Arterial Imaging to Assess Arteriosclerosis Angiology, December 1, 1997; 48(12): 1023 - 1030. [Abstract] [PDF]

				R. G. Hart and M. J.G. Harrison Aspirin Wars : The Optimal Dose of Aspirin to Prevent Stroke Stroke, April 1, 1996; 27(4): 585 - 587. [Full Text]

				C. Patrono and G. J. Roth Aspirin in Ischemic Cerebrovascular Disease : How Strong Is the Case for a Different Dosing Regimen? Stroke, April 1, 1996; 27(4): 756 - 760. [Abstract] [Full Text]

				A. Delcker, H.C. Diener, and H. Wilhelm Influence of Vascular Risk Factors for Atherosclerotic Carotid Artery Plaque Progression Stroke, November 1, 1995; 26(11): 2016 - 2022. [Abstract] [Full Text]

				D. Garcia-Dorado, P. Theroux, P. Tornos, A. Sambola, J. Oliveras, M. Santos, and J. S. Soler Previous Aspirin Use May Attenuate the Severity of the Manifestation of Acute Ischemic Syndromes Circulation, October 1, 1995; 92(7): 1743 - 1748. [Abstract] [Full Text]

				Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]

				HIGH-DOSE ASPIRIN MAY SLOW CAROTID ATHEROSCLEROSIS Journal Watch (General), June 29, 1993; 1993(629): 1 - 1. [Full Text]

				D. Pratico, C. Tillmann, Z.-B. Zhang, H. Li, and G. A. FitzGerald Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice PNAS, March 13, 2001; 98(6): 3358 - 3363. [Abstract] [Full Text] [PDF]